ACIP Votes to Approve That Tdap and Td Vaccines May Now Be Used Interchangeably

November 2019

Technically Speaking
Monthly Column by Deborah Wexler, MD
Deborah Wexler MD
IAC Executive Director Dr. Deborah Wexler writes Technically Speaking, a column featured in each issue of Vaccine Update for Healthcare Professionals, the monthly e-newsletter from the Vaccine Education Center (VEC) at the Children’s Hospital of Philadelphia. Technically Speaking columns cover practical topics in immunization delivery such as vaccine administration techniques, storage and handling, contraindications and precautions, and scheduling.
Subscribe to VEC’s Vaccine Update for Healthcare Professionals to stay up to date on vaccine-related issues, including reviews of recently published journal articles, media recaps, and announcements about new resources and webinars. To subscribe, visit the Vaccine Update Newsletter Sign-up Form
The archive of past Technically Speaking columns is also available.
ACIP Votes to Approve That Tdap and Td Vaccines May Now Be Used Interchangeably
Published November 2019
At CDC’s Advisory Committee of Immunization Practices (ACIP) meeting held in October, the committee voted unanimously to approve that Td and Tdap vaccines may be used interchangeably in almost all situations where currently only Td vaccine is recommended. Specifically, Tdap may now be used instead of Td in any of the following situations:

  • Decennial (every 10 years) Td booster
  • Tetanus prophylaxis for wound management
  • Catch-up immunization schedule for persons age 7 and older, including pregnant women

The Committee reached this decision after noting that there were no substantive safety concerns or increased adverse events when Tdap is given in place of Td. Several members also noted that this change supports commonly accepted clinical practice. ACIP also voted to approve Tdap for use in the Vaccines For Children (VFC) program.

Finally, ACIP also took this opportunity to clarify its recommendations on the use of Tdap vaccine in children who are 10 years of age. The current ACIP guidance, Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines: Recommendations of ACIP recommends that children 7–10 years of age who receive Tdap inadvertently or for catch-up immunization should be given an adolescent Tdap dose at age 11–12 years. However, both Tdap vaccines currently in use in the United States are licensed beginning at 10 years of age. Therefore, the Committee will issue a Policy Note in MMWR to clarify that children who receive a dose of Tdap at > 10 years of age do not need to repeat the Tdap dose at age 11–12 years.

Note: All recommendations approved by ACIP are provisional until they are approved by the CDC director and published in MMWR.

Presentation slides from the October ACIP meeting will be posted on the ACIP website in late November or early December.

ACIP Meeting Information web page

When you are on this page, click the tab titled “Meeting Materials” to access agendas, meeting minutes, and slide presentations.

This page was updated on .